ALIGNMENT WITH SEQ ID NO:1
ARAP ET AL.

ABG77468
ID ABG77468 standard; peptide; 14 AA.
XX
AC ABG77468;
XX
DT 05-NOV-2002 (first entry)
XX
DE Targetting peptide selective for human organ, tissue or cell type #1.
XX
KW Human; cytostatic; antiinflammatory; antidiabetic; cardiovascular;
KW immunomodulator; antibacterial; antiviral; gene therapy; cancer;
KW arthritis; diabetes; inflammatory disease; atherosclerosis;
KW autoimmune disease; bacterial infection; viral infection;
KW cardiovascular disease; degenerative disease.
XX
OS Homo sapiens.
XX
PN WO200220723-A2.
XX
PD 14-MAR-2002.
XX
PF 07-SEP-2001; 2001WO-US028044.
XX
PR 08-SEP-2000; 2000US-0231266P.
PR 17-JAN-2001; 2001US-00765101.
XX
PA (TEXA) UNIV TEXAS SYSTEM.
XX
PI Arap W, Pasqualini R;
XX
DR WPI; 2002-599247/64.
XX
PT New targeting peptides identified by phage display, useful for treating a
PT disease state, e.g. cancer, diabetes, inflammatory disease,
PT atherosclerosis, autoimmune disease, bacterial or viral infection or
PT cardiovascular disease.
XX
PS Claim 24; Page 113; 269pp; English.
XX
CC The invention describes an isolated peptide of 100 amino acids or less in
CC size. The peptide is useful for treating a disease state, e.g. cancer,
CC arthritis, diabetes, inflammatory disease, atherosclerosis, autoimmune
CC disease, bacterial infection, viral infection, cardiovascular disease or
CC degenerative disease. This sequence represents a human targeting peptide
CC selective for human organs, tissues or cell types
XX
SQ Sequence 14 AA;

Query Match 100.0%; Score 62; DB 5; Length 14;
Best Local Similarity 100.0%; Pred. No. 0.015;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 KLAKLAKKLAKLAK 14
              ||||||||||||||
Db          1 KLAKLAKKLAKLAK 14
```

****

ALIGNMENT WITH SEQ ID NO: 34
ARAP ET AL.

ABG77616
ID ABG77616 standard; peptide; 7 AA.
XX
AC ABG77616;
XX
DT 05-NOV-2002 (first entry)
XX
DE Targetting peptide selective for human organ, tissue or cell type #149.
XX
KW Human; cytostatic; antiinflammatory; antidiabetic; cardiovascular;
KW immunomodulator; antibacterial; antiviral; gene therapy; cancer;
KW arthritis; diabetes; inflammatory disease; atherosclerosis;
KW autoimmune disease; bacterial infection; viral infection;
KW cardiovascular disease; degenerative disease.
XX
OS Homo sapiens.
XX
PN WO200220723-A2.
XX
PD 14-MAR-2002.
XX
PF 07-SEP-2001; 2001WO-US028044.
XX
PR 08-SEP-2000; 2000US-0231266P.
PR 17-JAN-2001; 2001US-00765101.
XX
PA (TEXA) UNIV TEXAS SYSTEM.
XX
PI Arap W, Pasqualini R;
XX
DR WPI; 2002-599247/64.
XX
PT New targeting peptides identified by phage display, useful for treating a
PT disease state, e.g. cancer, diabetes, inflammatory disease,
PT atherosclerosis, autoimmune disease, bacterial or viral infection or
PT cardiovascular disease.
XX
PS Claim 16; Fig 2A; 269pp; English.
XX
CC The invention describes an isolated peptide of 100 amino acids or less in
CC size. The peptide is useful for treating a disease state, e.g. cancer,
CC arthritis, diabetes, inflammatory disease, atherosclerosis, autoimmune
CC disease, bacterial infection, viral infection, cardiovascular disease or
CC degenerative disease. This sequence represents a human targeting peptide
CC selective for human organs, tissues or cell types
XX
SQ Sequence 7 AA;

Query Match 100.0%; Score 30; DB 5; Length 7;
Best Local Similarity 100.0%; Pred. No. 2.9e+06;
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RRAGGS 6
||||||
Db 2 RRAGGS 7

```
**************************************************************************************
*

ALIGNMENT WITH SEQ ID NO: 1
ELLERBY ET AL.


AAB21900
ID   AAB21900 standard; peptide; 14 AA.
XX
AC   AAB21900;
XX
DT   22-MAR-2001  (first entry)
XX
DE   Antimicrobial pro-apoptotic peptide #1.
XX
KW   Cytostatic; homing pro-apoptotic conjugate; tumour; antimicrobial;
KW   breast; prostate; melanoma; cancer; Kaposi's sarcoma; amphipathic;
KW   alpha-helix.
XX
OS   Unidentified.
XX
FH   Key             Location/Qualifiers
FT   Misc-difference 1..14
FT                   /note= "Preferably D-form residues"
XX
PN   WO200042973-A2.
XX
PD   27-JUL-2000.
XX
PF   21-JAN-2000; 2000WO-US001602.
XX
PR   22-JAN-1999;    99US-00235902.
XX
PA   (BURN-) BURNHAM INST.
XX
PI   Ellerby HM, Bredesen DE, Pasqualini R, Ruoslahti EI;
XX
DR   WPI; 2000-499174/44.
XX
PT   Homing pro-apoptotic conjugate comprising a tumor homing molecule that
PT   selectively homes to a mammalian cell type or tissue linked to an
PT   antimicrobial peptide, useful for the treatment of prostate cancer.
XX
PS   Claim 4; Page 104; 118pp; English.
XX
CC   The present invention relates to homing pro-apoptotic conjugates,
CC   comprising of a tumour homing molecule that selectively homes to a
CC   mammalian cell type or tissue, linked to an antimicrobial peptide. The
CC   homing pro-apoptotic conjugates are selectively internalised by the
CC   mammalian cell type or tissue and exhibits high toxicity, especially to
CC   angiogenic vasculature. The antimicrobial peptide has low mammalian cell
CC   toxicity when not linked to the tumor homing molecule. The conjugates are
CC   useful for the treatment of cancer e.g. Kaposi's sarcoma, breast and
CC   prostate cancer or melanoma. The present sequence is one such
CC   antimicrobial peptide, which can be conjugated to a homing peptide to
CC   make the homing pro-apoptotic conjugates of the present invention. The
CC   present sequence has an amphipathic alpha-helical structure
XX
SQ   Sequence 14 AA;
```

```
  Query Match             100.0%;  Score 62;  DB 3;  Length 14;
  Best Local Similarity   100.0%;  Pred. No. 0.015;
  Matches   14;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 KLAKLAKKLAKLAK 14
              ||||||||||||||
Db          1 KLAKLAKKLAKLAK 14
```

****

ALIGNMENT WITH SEQ ID NO:30
THAKUR ET AL.

```
ID   AAU97785 standard; peptide; 4 AA.
XX
AC   AAU97785;
XX
DT   07-OCT-2002  (first entry)
XX
DE   Tumour specific peptide sequence #1.
XX
KW   Tumour imaging; radiodiagnosis; tumour; cancer; breast; ovary; prostate;
KW   endometrium; bladder; lung; oesophagus; colon; pancreas; brain;
KW   liver metastasis; neuroendocrine tumour; carcinoid.
XX
OS   Unidentified.
XX
FH   Key             Location/Qualifiers
FT   Modified-site   1
FT                   /label= OTHER
FT                   /note= "OTHER= Optionally labelled with technetium-99m"
FT   Misc-difference 2
FT                   /note= "D-form residue"
FT   Modified-site   4
FT                   /label= OTHER
FT                   /note= "OTHER= Optionally linked with 4-aminobutyric
FT                   acid"
XX
PN   US6395255-B1.
XX
PD   28-MAY-2002.
XX
PF   15-JUN-1999;    99US-00333842.
XX
PR   15-JUN-1998;    98US-0089364P.
XX
PA   (UYJE-) UNIV JEFFERSON THOMAS.
XX
PI   Thakur ML;
XX
DR   WPI; 2002-556090/59.
XX
PT   Compositions, useful as radiodiagnostic agent for imaging tumors,
PT   comprises tumor specific sequence linked to radionuclide moiety.
XX
PS   Claim 7; Col 17; 17pp; English.
XX
CC   The invention relates to a composition comprising a tumour specific
CC   sequence linked to a radionuclide moiety. A reagent for radiolabelling a
```

CC tumour imaging agent comprises four amino acids, which covalently link
CC the radionuclide to the amino group, complexed with a tumour specific
CC sequence and enables the reagent to bind to a tumour. The composition is
CC useful as a radiodiagnostic agent for imaging tumours (such as breast,
CC ovarian, endometrial, prostate, bladder, lung, oesophageal, colonic and
CC pancreatic cancers and neuroendocrine and brain tumors), liver
CC metastases, and carcinoids in mammals. This sequence represents a
CC radionuclide moiety used in the scope of the invention
XX
SQ Sequence 4 AA;

Query Match 100.0%; Score 16; DB 5; Length 4;
Best Local Similarity 100.0%; Pred. No. 2.9e+06;
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 AGG 3
              |||
Db          2 AGG 4
```